Stockscreener 앱 받기
2.92
2.82%
0.08
시간 외 거래:
2.92
전일 마감가:
$2.84
열려 있는:
$2.8
하루 거래량:
2.92M
Relative Volume:
1.09
시가총액:
$988.93M
수익:
$796.85M
순이익/손실:
$30.44M
주가수익비율:
34.68
EPS:
0.0842
순현금흐름:
$93.88M
1주 성능:
+14.51%
1개월 성능:
+36.45%
6개월 성능:
-6.11%
1년 성능:
-31.13%
1일 변동 폭
$2.72
$2.94
1주일 범위
$2.44
$2.94
52주 변동 폭
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
명칭
Goodrx Holdings Inc
전화
(855) 268-2822
주소
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, BTSG, TEM, HQY, DOCS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
2.92 | 988.93M | 796.85M | 30.44M | 93.88M | 0.0842 |
VEEV
Veeva Systems Inc
|
166.34 | 27.15B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
54.83 | 10.63B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
49.86 | 8.95B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
84.84 | 7.17B | 1.31B | 215.20M | 408.32M | 2.4627 |
DOCS
Doximity Inc
|
25.98 | 4.80B | 637.78M | 239.40M | 307.21M | 1.1909 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-27 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2026-01-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-08-11 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | 개시 | Mizuho | Neutral |
| 2024-08-09 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-02-26 | 개시 | Leerink Partners | Outperform |
| 2024-01-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-08-10 | 업그레이드 | DA Davidson | Neutral → Buy |
| 2023-07-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | 개시 | Citigroup | Buy |
| 2022-11-04 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-08-12 | 개시 | DA Davidson | Neutral |
| 2022-06-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-06-06 | 재개 | BofA Securities | Buy |
| 2022-06-01 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-05-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | 개시 | Wells Fargo | Equal Weight |
| 2022-04-07 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Neutral |
| 2022-03-15 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | 재확인 | Barclays | Overweight |
| 2022-03-01 | 재확인 | BofA Securities | Neutral |
| 2022-03-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-01 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | 재확인 | Evercore ISI | Outperform |
| 2022-03-01 | 재확인 | Goldman | Buy |
| 2022-03-01 | 재확인 | JP Morgan | Underweight |
| 2022-03-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-03-01 | 재확인 | SVB Leerink | Outperform |
| 2022-01-07 | 개시 | Goldman | Buy |
| 2021-12-21 | 개시 | Stephens | Overweight |
| 2021-12-02 | 개시 | Jefferies | Buy |
| 2021-08-31 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-08-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | 개시 | Robert W. Baird | Neutral |
| 2021-04-06 | 재개 | Evercore ISI | Outperform |
| 2021-01-25 | 개시 | Guggenheim | Buy |
| 2020-11-19 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | 개시 | Barclays | Equal Weight |
| 2020-10-19 | 개시 | BofA Securities | Neutral |
| 2020-10-19 | 개시 | Citigroup | Buy |
| 2020-10-19 | 개시 | Cowen | Outperform |
| 2020-10-19 | 개시 | Credit Suisse | Outperform |
| 2020-10-19 | 개시 | Deutsche Bank | Hold |
| 2020-10-19 | 개시 | Goldman | Neutral |
| 2020-10-19 | 개시 | JP Morgan | Neutral |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
| 2020-10-19 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | 개시 | SVB Leerink | Outperform |
| 2020-10-19 | 개시 | UBS | Buy |
모두보기
Goodrx Holdings Inc 주식(GDRX)의 최신 뉴스
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q1 2026 Earnings Call Transcript - Insider Monkey
GoodRx Earnings Call Highlights Pharma Direct Momentum - TipRanks
GoodRx (GDRX) Q1 2026 Earnings Call Transcript - The Globe and Mail
GoodRx (GDRX) Reports Strong Q1 2026 Earnings and Raises Guidance - GuruFocus
GoodRx (GDRX) Q1 earnings: Taking a look at key metrics versus estimates - MSN
GoodRx Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: GoodRx Q1 2026 revenue exceeds forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: GoodRx Q1 2026 revenue exceeds forecasts - Investing.com
GoodRx Holdings, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Q1 2026 GoodRx Holdings Inc Earnings Call Transcript - GuruFocus
GoodRx Holdings, Inc. (GDRX) Reports In-Line Q1 EPS ; Offers Guidance - StreetInsider
Number of shareholders of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
GoodRx Holdings, Inc. (GDRX) Q1 earnings match estimates - MSN
GoodRx Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates - Yahoo Finance
GoodRx (NASDAQ:GDRX) Beats Q1 CY2026 Sales Expectations - Barchart
GDRX: Pharma Direct revenue soared 82% in Q1 2026, offsetting declines in other segments - TradingView
GoodRx Holdings Q1 Adjusted Earnings, Revenue Fall - marketscreener.com
GoodRx (NASDAQ: GDRX) Q1 2026 shifts from Rx volume to Pharma Direct growth - Stock Titan
GoodRx Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
GoodRx Reports First Quarter 2026 Results - Business Wire
What's Going On With GoodRx Stock Thursday? - Sahm
3 Promising Penny Stocks With Market Caps Up To $900M - simplywall.st
GoodRx (GDRX) Reports Earnings Tomorrow: What To Expect - Barchart
GoodRx Holdings Inc expected to post earnings of 7 cents a shareEarnings Preview - TradingView
GDRX SEC FilingsGoodrx Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
GoodRx (NASDAQ: GDRX) CAO Thomas Chan reports stock, options and RSUs - Stock Titan
Why GoodRx (GDRX) Stock Is Trading Up Today - Barchart.com
GoodRx offers oral semaglutide starting at $149 per month By Investing.com - Investing.com India
GoodRx expands offerings to now include Ozempic® pill for type 2 diabetes patients - marketscreener.com
GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients - Quantisnow
A new Ozempic pill now starts at $149 a month through GoodRx - Stock Titan
GDRX Forecast, Price Target & Analyst Ratings | GOODRX HOLDINGS INC-CLASS A (NASDAQ:GDRX) - ChartMill
[ARS] GoodRx Holdings, Inc. SEC Filing - Stock Titan
Executive pay, auditor change headline GoodRx (NASDAQ: GDRX) 2026 vote - Stock Titan
GDRX vs. HQY: Which Stock Is the Better Value Option? - MSN
GoodRx (GDRX) Q2 2024 earnings summary - Quartr
GoodRx won't be participating with TrumpRx: report - MSN
What's going on with GoodRx stock Thursday? - MSN
GoodRx Holdings, Inc. Appoints New Chief Accounting Officer and Files Form 8-K with SEC - Minichart
GoodRx appoints Thomas Chan as chief accounting officer By Investing.com - Investing.com India
GoodRx Names Thomas Chan Chief Accounting Officer - TipRanks
GoodRx appoints Thomas Chan as chief accounting officer - Investing.com
GoodRx names Thomas Chan as Chief Accounting Officer - TradingView
GoodRx (NASDAQ: GDRX) appoints Thomas Chan as new Chief Accounting Officer - Stock Titan
OptimizeRx vs. GoodRx: Which Digital Health Stock is the Better Buy? - The Globe and Mail
GDRX GoodRx Holdings shares climb 4.41 percent after Q4 2025 results despite a minor EPS miss against analyst expectations.Social Trade Signals - Cổng thông tin điện tử tỉnh Tây Ninh
GDRX (GoodRx Holdings Inc.) drops 3.4% today after Q4 2025 EPS narrowly falls short of analyst expectations.Risk Event - Xã Thanh Hà
GoodRx Holdings (GDRX) Sector Leadership | Q4 2025: EPS Misses EstimatesSector Outperform - Cổng thông tin điện tử tỉnh Tây Ninh
Goodrx Holdings Inc (GDRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.76%
자본화:
|
볼륨(24시간):